Vistin Pharma ASA (LON:0RAM)
London
· Delayed Price · Currency is GBP · Price in NOK 22.90
-1.50 (-6.15%)
At close: Jan 15, 2025
Vistin Pharma ASA Balance Sheet
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 12.79 | 26.2 | 1.44 | 35.75 | 77.04 | Upgrade
|
| Cash & Short-Term Investments | 12.79 | 26.2 | 1.44 | 35.75 | 77.04 | Upgrade
|
| Cash Growth | -51.18% | 1726.06% | -95.99% | -53.60% | -75.90% | Upgrade
|
| Accounts Receivable | 44.28 | 47.02 | 66.16 | 40.25 | 30.4 | Upgrade
|
| Other Receivables | 9.45 | 12.56 | 5.01 | 2.85 | 1.45 | Upgrade
|
| Receivables | 53.73 | 59.59 | 71.17 | 43.09 | 31.85 | Upgrade
|
| Inventory | 76.67 | 80.17 | 83.45 | 42.91 | 31.79 | Upgrade
|
| Prepaid Expenses | - | 2.81 | 3.14 | 16.09 | 0.85 | Upgrade
|
| Total Current Assets | 143.19 | 168.77 | 159.18 | 137.83 | 141.53 | Upgrade
|
| Property, Plant & Equipment | 229.6 | 219.98 | 219.43 | 167.46 | 145.26 | Upgrade
|
| Long-Term Deferred Tax Assets | - | 14.64 | 28.6 | 27.86 | 35.13 | Upgrade
|
| Other Long-Term Assets | 12.16 | - | - | 0 | - | Upgrade
|
| Total Assets | 384.95 | 403.4 | 407.21 | 333.15 | 321.92 | Upgrade
|
| Accounts Payable | 13.05 | 18.92 | 25.91 | 20.81 | 17.89 | Upgrade
|
| Accrued Expenses | - | 16.6 | 14.67 | 16.58 | 11.69 | Upgrade
|
| Short-Term Debt | - | - | 45.14 | - | - | Upgrade
|
| Current Portion of Leases | 0.87 | 1 | 1.07 | 0.88 | - | Upgrade
|
| Other Current Liabilities | 53.55 | 32.95 | 30.78 | 2.78 | 2.62 | Upgrade
|
| Total Current Liabilities | 67.48 | 69.47 | 117.57 | 41.04 | 32.2 | Upgrade
|
| Long-Term Leases | 1.33 | 2.29 | 2.96 | 0.51 | - | Upgrade
|
| Other Long-Term Liabilities | - | 0 | -0 | 0 | 0.98 | Upgrade
|
| Total Liabilities | 75.41 | 80.63 | 133.73 | 57.38 | 49.51 | Upgrade
|
| Common Stock | 44.35 | 44.35 | 44.35 | 44.35 | 44.35 | Upgrade
|
| Additional Paid-In Capital | 129.3 | 206.89 | 206.89 | 206.89 | 229.06 | Upgrade
|
| Retained Earnings | 135.89 | 71.54 | 22.26 | 24.54 | -1 | Upgrade
|
| Shareholders' Equity | 309.54 | 322.77 | 273.49 | 275.77 | 272.41 | Upgrade
|
| Total Liabilities & Equity | 384.95 | 403.4 | 407.21 | 333.15 | 321.92 | Upgrade
|
| Total Debt | 2.2 | 3.29 | 49.17 | 1.39 | - | Upgrade
|
| Net Cash (Debt) | 10.59 | 22.91 | -47.73 | 34.36 | 77.04 | Upgrade
|
| Net Cash Growth | -53.77% | - | - | -55.40% | -75.71% | Upgrade
|
| Net Cash Per Share | 0.24 | 0.52 | -1.08 | 0.77 | 1.74 | Upgrade
|
| Filing Date Shares Outstanding | 44.34 | 44.34 | 44.34 | 44.34 | 44.34 | Upgrade
|
| Total Common Shares Outstanding | 44.34 | 44.34 | 44.34 | 44.34 | 44.34 | Upgrade
|
| Working Capital | 75.71 | 99.3 | 41.61 | 96.8 | 109.32 | Upgrade
|
| Book Value Per Share | 6.98 | 7.28 | 6.17 | 6.22 | 6.14 | Upgrade
|
| Tangible Book Value | 309.54 | 322.77 | 273.49 | 275.77 | 272.41 | Upgrade
|
| Tangible Book Value Per Share | 6.98 | 7.28 | 6.17 | 6.22 | 6.14 | Upgrade
|
| Machinery | - | 263.53 | 253.37 | - | 87.23 | Upgrade
|
| Construction In Progress | - | 17.91 | 10.24 | - | 56.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.